

Shivam Gandhi, Eren Shin, David An, Xichen Zhang

INTRODUC TION

In the current era, the existence of rare diseases still brings great suffering to patients and families. As a result, there are still many questions to be explored around the genetic architecture of rare diseases.

First, we have to understand that one of the main challenges in the genetic structure of rare diseases comes from the pervasive genetic interactions, a phenomenon known as **epistasis**.



Example: Patients with Epidermolysis Bullosa: There may be 500,000+ people living with EB

Healthcare cost:


worldwide.

Ranges from \$50,000 to over \$400,000 per year per patient in U.S.

Treatments:

Very Limited!

Genetic Interactions Complicate Our Understanding of Disease




- In cystic fibrosis, variations in TGFB1 influence disease severity
- In retinitis pigmentosa, mutations in two genes together cause disease
- In sickle cell disease, levels of hemoglobin (BCL11A, HBS1L, etc.) determine the severity of sickling
- Dominance relationships make diagnosing autosomal recessive diseases difficult

RareLink: Detecting Genetic Interactions With Deep Learning

Recent advances in ML for biology makes DNA LLMs a prime candidate for detecting genetic interactions


Evo



Data sources: ClinVar, OMIM, COSMIC

ML Models: GPN-MSA, Evo

RareLink predicts LoF genetic interaction between disease implicated variants in LMNA




From our function score, we calculate a value of epistatic strength E:

E ≪ 0: LoF interaction


E = 0: no interaction

E » 0: GoF interaction

RareLink Has a Web App to Aid







Pick one specific gene -> choose one/two variants -> Generate the Disease report

Future Directions

Scalability

 Use our dataset of all localized rare disease variant pairs in the human genome to flesh out the range of variants accessible on Rarelink's platform.

Biological Interpretability

- Sparse autoencoders can detect biologically relevant features of DNA sequences. Can we detect new disease mechanisms and potentially therapeutic targets?

Refining Our Metrics

- How valid are our epistasis metrics? Are the interactions we're detecting real? We aim to compare our metrics to data from CRISPR screens to get as accurate as possible

Fleshing Out a User Friendly Platform

 How will clinicians use RareLink to get patients a better diagnosis? How can we improve the workflow in rare disease care? We aim to do user interviews across providers and researchers.

Who are we?



Xichen Zhang

Undergraduate at SUNY Buffalo studying Applied Math with computing concentration.



Eren Shin

Alumnus of MIT 2023, Associate Computational Biologist at MGH/Broad Institute



David An

Undergraduate at
Harvard studying Human
Developmental and
Regenerative Biology



Shivam Gandhi

PhD student at Harvard studying mathematical and machine learning methods for genetics